Aqualung Therapeutics Overview
- Year Founded
-
2010
- Status
-
Private
- Employees
-
5
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$3.25M
- Investors
-
8
Aqualung Therapeutics General Information
Description
Developer of an immune-focused biologic platform designed for serious inflammatory disorders. The company's strategies include the deployment of a humanized monoclonal antibody that targets a novel inflammatory mediator, eNAMPT, enabling medical practitioners to address the unmet need for novel, effective therapies for VILI, idiopathic pulmonary fibrosis and pulmonary hypertension in patients.
Contact Information
Website
www.aqualungtherapeutics.comCorporate Office
- 6080 North Pinchot Road
- Tucson, AZ 85750
- United States
Corporate Office
- 6080 North Pinchot Road
- Tucson, AZ 85750
- United States
Aqualung Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 9. Later Stage VC | 04-Apr-2023 | $3.25M | Completed | Clinical Trials - Phase 2 | ||
| 8. Grant | 20-Aug-2022 | Completed | Clinical Trials - Phase 2 | |||
| 7. Later Stage VC (Series A) | 27-Jun-2022 | Completed | Clinical Trials - Phase 2 | |||
| 6. Grant | 01-Jan-2020 | Completed | Pre-Clinical Trials | |||
| 5. Grant | 01-Jun-2020 | Completed | Pre-Clinical Trials | |||
| 4. Later Stage VC (Series A) | 13-Jan-2020 | Cancelled | Pre-Clinical Trials | |||
| 3. Seed Round | 11-Oct-2019 | Completed | Pre-Clinical Trials | |||
| 2. Grant | 01-Jan-2019 | $2.15M | Completed | Pre-Clinical Trials | ||
| 1. Accelerator/Incubator | 01-Jan-2018 | Completed | Pre-Clinical Trials |
Aqualung Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Aqualung Therapeutics Comparisons
Industry
Financing
Details
Aqualung Therapeutics Competitors (24)
One of Aqualung Therapeutics’s 24 competitors is Baliopharm, a Venture Capital-Backed company based in Basel, Switzerland.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Baliopharm | Venture Capital-Backed | Basel, Switzerland | ||||
| Attune Pharmaceuticals | Venture Capital-Backed | New York, NY | ||||
| Enterprise Therapeutics | Venture Capital-Backed | Brighton, United Kingdom | ||||
| Redx Pharma | Venture Capital-Backed | Macclesfield, United Kingdom | ||||
| Verona Pharma | Corporate Backed or Acquired | London, United Kingdom |
Aqualung Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Aqualung Therapeutics Patents
Aqualung Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-11142586-B2 | Anti-human nicotinamide phosphoribosyltransferase (nampt) antibodies | Active | 07-Aug-2019 | ||
| US-11466099-B2 | Anti-human nicotinamide phosphoribosyltransferase (nampt) antibodies | Active | 07-Aug-2019 | ||
| US-20220056152-A1 | Anti-human nicotinamide phosphoribosyltransferase (nampt) antibodies | Active | 07-Aug-2019 | ||
| US-20230220113-A1 | Anti-human nicotinamide phosphoribosyltransferase (nampt) antibodies | Inactive | 07-Aug-2019 | ||
| AU-2020325315-A1 | Anti-nampt antibodies and uses thereof | Pending | 07-Aug-2019 | C07K16/40 |
Aqualung Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Aqualung Therapeutics Investors (8)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| 7G Bioventures | Venture Capital | Minority | ||
| Arizona State University | University | Minority | ||
| Florida Opportunity Fund | Venture Capital | Minority | ||
| National Institute of Diabetes and Digestive and Kidney Diseases | Government | |||
| JSR Life Sciences | Corporation | Minority |
Aqualung Therapeutics FAQs
-
When was Aqualung Therapeutics founded?
Aqualung Therapeutics was founded in 2010.
-
Where is Aqualung Therapeutics headquartered?
Aqualung Therapeutics is headquartered in Tucson, AZ.
-
What is the size of Aqualung Therapeutics?
Aqualung Therapeutics has 5 total employees.
-
What industry is Aqualung Therapeutics in?
Aqualung Therapeutics’s primary industry is Drug Discovery.
-
Is Aqualung Therapeutics a private or public company?
Aqualung Therapeutics is a Private company.
-
What is the current valuation of Aqualung Therapeutics?
The current valuation of Aqualung Therapeutics is .
-
What is Aqualung Therapeutics’s current revenue?
The current revenue for Aqualung Therapeutics is .
-
How much funding has Aqualung Therapeutics raised over time?
Aqualung Therapeutics has raised $9.6M.
-
Who are Aqualung Therapeutics’s investors?
7G Bioventures, Arizona State University, Florida Opportunity Fund, National Institute of Diabetes and Digestive and Kidney Diseases, and JSR Life Sciences are 5 of 8 investors who have invested in Aqualung Therapeutics.
-
Who are Aqualung Therapeutics’s competitors?
Baliopharm, Attune Pharmaceuticals, Enterprise Therapeutics, Redx Pharma, and Verona Pharma are some of the 24 competitors of Aqualung Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
